NASDAQ:HTBX Heat Biologics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Heat Biologics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.38 -0.02 (-1.42 %) (As of 09/21/2020 03:27 PM ET) Add Compare Share Today's Range$1.33Now: $1.39▼$1.4250-Day Range$1.02MA: $1.53▼$2.2952-Week Range$0.20Now: $1.39▼$4.30Volume199,733 shsAverage Volume18.81 million shsMarket Capitalization$205.76 millionP/E RatioN/ADividend YieldN/ABeta0.45 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Heat Biologics, Inc., a biopharmaceutical company, focuses on developing approaches to activate and co-stimulate a patient's immune system against cancer in the United States. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors hot and be administered in combination with checkpoint inhibitors and other immuno-modulators to enhance clinical effectiveness. Its TCAP product candidates include ImPACT platform technology that develops product candidates consist of live, allogeneic off-the-shelf genetically-modified, and irradiated human cancer cells; and Combination Pan-antigen Cytotoxic Therapy, a dual-acting immunotherapy designed to deliver T-cell activation and enhanced, and T-cell specific co-stimulation in a single treatment. The company is developing HS-110 that is in Phase 2 clinical trial in combination with Bristol-Myers Squibb's nivolumab (Opdivo) for the treatment of non-small cell lung cancer. Its preclinical trial product candidates include HS-130 for the treatment of non-muscle invasive bladder cancer; and PTX-35 and PTX-15 for treating tumors and hematologic malignancies. The company was founded in 2008 and is headquartered in Durham, North Carolina.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingHeat Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.00, Heat Biologics has a forecasted upside of 44.9% from its current price of $1.38.Amount of Analyst CoverageHeat Biologics has received no research coverage in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesHeat Biologics has received 362 “outperform” votes. (Add your “outperform” vote.)Underperform VotesHeat Biologics has received 253 “underperform” votes. (Add your “underperform” vote.)Community SentimentHeat Biologics has received 58.86% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Heat Biologics and other stocks. Vote “Outperform” if you believe HTBX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HTBX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldHeat Biologics does not currently pay a dividend.Dividend GrowthHeat Biologics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Heat Biologics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.50% of the stock of Heat Biologics is held by insiders.Percentage Held by InstitutionsOnly 7.06% of the stock of Heat Biologics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Heat Biologics are expected to grow in the coming year, from ($0.27) to ($0.26) per share.Price to Book Value per Share RatioHeat Biologics has a P/B Ratio of 3.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:HTBX Previous Symbol CUSIPN/A CIK1476963 Webwww.heatbio.com Phone919-240-7133Debt Debt-to-Equity Ratio0.03 Current Ratio7.66 Quick Ratio7.66Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.05 million Price / Sales67.46 Cash FlowN/A Price / Cash FlowN/A Book Value$0.39 per share Price / Book3.55Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-20,020,000.00 Net Margins-579.28% Return on Equity-75.71% Return on Assets-53.27%Miscellaneous Employees30 Outstanding Shares148,561,000Market Cap$205.76 million Next Earnings Date11/20/2020 (Estimated) OptionableNot Optionable $1.38 -0.02 (-1.42 %) (As of 09/21/2020 03:27 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive HTBX News and Ratings via Email Sign-up to receive the latest news and ratings for HTBX and its competitors with MarketBeat's FREE daily newsletter. Heat Biologics (NASDAQ:HTBX) Frequently Asked Questions How has Heat Biologics' stock price been impacted by COVID-19? Heat Biologics' stock was trading at $0.70 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HTBX shares have increased by 97.1% and is now trading at $1.38. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Heat Biologics? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heat Biologics in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heat Biologics. When is Heat Biologics' next earnings date? Heat Biologics is scheduled to release its next quarterly earnings announcement on Friday, November 20th 2020. View our earnings forecast for Heat Biologics. How were Heat Biologics' earnings last quarter? Heat Biologics Inc (NASDAQ:HTBX) announced its earnings results on Friday, August, 7th. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.08) by $0.03. The biopharmaceutical company had revenue of $0.59 million for the quarter, compared to the consensus estimate of $0.60 million. Heat Biologics had a negative net margin of 579.28% and a negative return on equity of 75.71%. View Heat Biologics' earnings history. When did Heat Biologics' stock split? How did Heat Biologics' stock split work? Heat Biologics's stock reverse split on the morning of Monday, January 22nd 2018. The 1-10 reverse split was announced on Friday, January 19th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, January 19th 2018. An investor that had 100 shares of Heat Biologics stock prior to the reverse split would have 10 shares after the split. What price target have analysts set for HTBX? 1 brokers have issued 1 year price objectives for Heat Biologics' shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate Heat Biologics' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 44.9% from the stock's current price. View analysts' price targets for Heat Biologics. Are investors shorting Heat Biologics? Heat Biologics saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 7,830,000 shares, an increase of 52.9% from the August 15th total of 5,120,000 shares. Based on an average daily volume of 31,230,000 shares, the short-interest ratio is currently 0.3 days. View Heat Biologics' Short Interest. Who are some of Heat Biologics' key competitors? Some companies that are related to Heat Biologics include VBI Vaccines (VBIV), Protagonist Therapeutics (PTGX), resTORbio (TORC), Frequency Therapeutics (FREQ), Kadmon (KDMN), Endo International (ENDP), Phibro Animal Health (PAHC), Spectrum Pharmaceuticals (SPPI), Wave Life Sciences (WVE), ImmunoGen (IMGN), Collegium Pharmaceutical (COLL), Emisphere Technologies (EMIS), DiaMedica Therapeutics (DMCAF), Cara Therapeutics (CARA) and Omeros (OMER). View all competitors. What other stocks do shareholders of Heat Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Heat Biologics investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), BioNano Genomics (BNGO), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), ADMA Biologics (ADMA), Novan (NOVN) and VBI Vaccines (VBIV). Who are Heat Biologics' key executives? Heat Biologics' management team includes the following people: Mr. Jeffrey Alan Wolf, Founder, Chairman, CEO & Pres (Age 56)Dr. Jeff T. Hutchins, Chief Scientific Officer & COO (Age 60)Mr. Robert J. Jakobs, VP of Fin., Sec. & Controller (Age 64)Dr. Justin Stebbing M.D., M.A., FRCP, FRCPath, Ph.D., Chief Medical Advisor and Member of Scientific & Clinical Advisory BoardColonel George E. Peoples Jr., M.D., FACS, Chief Medical Advisor What is Heat Biologics' stock symbol? Heat Biologics trades on the NASDAQ under the ticker symbol "HTBX." Who are Heat Biologics' major shareholders? Heat Biologics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Magnus Financial Group LLC (1.32%), Virtu Financial LLC (0.52%), HighTower Advisors LLC (0.03%), Meitav Dash Investments Ltd. (0.02%) and Biltmore Family Office LLC (0.04%). View institutional ownership trends for Heat Biologics. Which institutional investors are buying Heat Biologics stock? HTBX stock was acquired by a variety of institutional investors in the last quarter, including Magnus Financial Group LLC, Virtu Financial LLC, HighTower Advisors LLC, Biltmore Family Office LLC, and Meitav Dash Investments Ltd.. View insider buying and selling activity for Heat Biologics. How do I buy shares of Heat Biologics? Shares of HTBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Heat Biologics' stock price today? One share of HTBX stock can currently be purchased for approximately $1.38. How big of a company is Heat Biologics? Heat Biologics has a market capitalization of $205.01 million and generates $3.05 million in revenue each year. Heat Biologics employs 30 workers across the globe. What is Heat Biologics' official website? The official website for Heat Biologics is www.heatbio.com. How can I contact Heat Biologics? Heat Biologics' mailing address is 627 DAVIS DRIVE SUITE 400, MORRISVILLE NC, 27560. The biopharmaceutical company can be reached via phone at 919-240-7133 or via email at [email protected] This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
